337 related articles for article (PubMed ID: 31864301)
1. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction.
Li Y; Bian Y; Wang K; Wan XP
BMC Med Genet; 2019 Dec; 20(1):202. PubMed ID: 31864301
[TBL] [Abstract][Full Text] [Related]
2. Phenotype of POLE-mutated endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Rau TT; Mueller MD; Epstein E; Carlson JW
PLoS One; 2019; 14(3):e0214318. PubMed ID: 30917185
[TBL] [Abstract][Full Text] [Related]
3. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
[TBL] [Abstract][Full Text] [Related]
4. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis.
McAlpine JN; Chiu DS; Nout RA; Church DN; Schmidt P; Lam S; Leung S; Bellone S; Wong A; Brucker SY; Lee CH; Clarke BA; Huntsman DG; Bernardini MQ; Ngeow J; Santin AD; Goodfellow P; Levine DA; Köbel M; Kommoss S; Bosse T; Gilks CB; Talhouk A
Cancer; 2021 Jul; 127(14):2409-2422. PubMed ID: 33793971
[TBL] [Abstract][Full Text] [Related]
6. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.
Bellone S; Centritto F; Black J; Schwab C; English D; Cocco E; Lopez S; Bonazzoli E; Predolini F; Ferrari F; Silasi DA; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2015 Jul; 138(1):11-7. PubMed ID: 25931171
[TBL] [Abstract][Full Text] [Related]
7. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women.
He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T
Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323
[TBL] [Abstract][Full Text] [Related]
8. Autocrine motility factor promotes endometrial cancer progression by targeting GPER-1.
Li Y; Jia Y; Bian Y; Tong H; Qu J; Wang K; Wan XP
Cell Commun Signal; 2019 Mar; 17(1):22. PubMed ID: 30836961
[TBL] [Abstract][Full Text] [Related]
9. Interpretation of somatic POLE mutations in endometrial carcinoma.
León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
[TBL] [Abstract][Full Text] [Related]
10. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
Bellone S; Bignotti E; Lonardi S; Ferrari F; Centritto F; Masserdotti A; Pettinella F; Black J; Menderes G; Altwerger G; Hui P; Lopez S; de Haydu C; Bonazzoli E; Predolini F; Zammataro L; Cocco E; Ferrari F; Ravaggi A; Romani C; Facchetti F; Sartori E; Odicino FE; Silasi DA; Litkouhi B; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2017 Jan; 144(1):146-152. PubMed ID: 27894751
[TBL] [Abstract][Full Text] [Related]
11. Regulation of phosphoglucose isomerase/autocrine motility factor activities by the poly(ADP-ribose) polymerase family-14.
Yanagawa T; Funasaka T; Tsutsumi S; Hu H; Watanabe H; Raz A
Cancer Res; 2007 Sep; 67(18):8682-9. PubMed ID: 17875708
[TBL] [Abstract][Full Text] [Related]
12. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
[TBL] [Abstract][Full Text] [Related]
13. The complex biology of autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and its receptor, the gp78/AMFR E3 ubiquitin ligase.
Fairbank M; St-Pierre P; Nabi IR
Mol Biosyst; 2009 Aug; 5(8):793-801. PubMed ID: 19603112
[TBL] [Abstract][Full Text] [Related]
14. Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis.
McConechy MK; Talhouk A; Leung S; Chiu D; Yang W; Senz J; Reha-Krantz LJ; Lee CH; Huntsman DG; Gilks CB; McAlpine JN
Clin Cancer Res; 2016 Jun; 22(12):2865-73. PubMed ID: 26763250
[TBL] [Abstract][Full Text] [Related]
15. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA
PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130
[TBL] [Abstract][Full Text] [Related]
16. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
[TBL] [Abstract][Full Text] [Related]
17. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH
Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics and prognostic value of POLE mutations in endometrial cancer: A systematic review and meta-analysis.
He Y; Wang T; Li N; Yang B; Hu Y
Medicine (Baltimore); 2020 Feb; 99(8):e19281. PubMed ID: 32080141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]